SARS-CoV-2 antibody detection in skilled nursing facility residents.
Aged
Aged, 80 and over
Asymptomatic Infections
/ epidemiology
COVID-19
/ blood
COVID-19 Nucleic Acid Testing
/ statistics & numerical data
COVID-19 Serological Testing
/ methods
Early Diagnosis
Electronic Health Records
/ statistics & numerical data
Female
Health Services Needs and Demand
Humans
Male
Prevalence
SARS-CoV-2
/ immunology
Skilled Nursing Facilities
/ standards
Symptom Assessment
/ methods
United States
/ epidemiology
COVID19
SARS-CoV-2
nursing home
serology
skilled nursing facility
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
15
01
2021
received:
08
01
2021
accepted:
21
01
2021
pubmed:
6
2
2021
medline:
21
7
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
To describe the frequency and timing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody detection in a convenience sample of skilled nursing facility (SNF) residents with and without confirmed SARS-CoV-2 infection. Retrospective analysis of SNF electronic health records. Qualitative SARS-CoV-2 antibody test results were available from 81 SNFs in 16 states. Six hundred and sixty nine SNF residents who underwent both polymerase chain reaction (PCR) and antibody testing for SARS-CoV-2. Presence of SARS-CoV-2 antibodies following the first positive PCR test for confirmed cases, or first PCR test for non-cases. Among 397 residents with PCR-confirmed infection, antibodies were detected in 4 of 7 (57.1%) tested within 7-14 days of their first positive PCR test; in 44 of 47 (93.6%) tested within 15-30 days; in 182 of 219 (83.1%) tested within 31-60 days; and in 110 of 124 (88.7%) tested after 60 days. Among 272 PCR negative residents, antibodies were detected in 2 of 9 (22.2%) tested within 7-14 days of their first PCR test; in 41 of 81 (50.6%) tested within 15-30 days; in 65 of 148 (43.9%) tested within 31-60 days; and in 9 of 34 (26.5%) tested after 60 days. No significant differences in baseline resident characteristics or symptoms were observed between those with versus without antibodies. These findings suggest that vulnerable older adults can mount an antibody response to SARS-CoV-2, and that antibodies are most likely to be detected within 15-30 days of diagnosis. That antibodies were detected in a large proportion of residents with no confirmed SARS-CoV-2 infection highlights the complexity of identifying who is infected in real time. Frequent surveillance and diagnostic testing based on low thresholds of clinical suspicion for symptoms and/or exposure will remain critical to inform strategies designed to mitigate outbreaks in SNFs while community SARS-CoV-2 prevalence remains high.
Identifiants
pubmed: 33544876
doi: 10.1111/jgs.17061
pmc: PMC8013911
mid: NIHMS1672137
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1722-1728Subventions
Organisme : NIA NIH HHS
ID : P01 AG027296
Pays : United States
Organisme : NIA NIH HHS
ID : 3P01AG027296-11S1
Pays : United States
Organisme : National Institute of Allergy and Infectious Disease
ID : R01AI129709
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The American Geriatrics Society.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Am Geriatr Soc. 2021 Jul;69(7):1722-1728
pubmed: 33544876
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Med Care. 2017 Sep;55(9):e68-e72
pubmed: 25763665
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1762-1766
pubmed: 33237893
J Am Geriatr Soc. 2018 May;66(5):976-981
pubmed: 29500822
J Gerontol A Biol Sci Med Sci. 1999 Nov;54(11):M546-53
pubmed: 10619316
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Emerg Infect Dis. 2020 Oct;26(10):2484-2487
pubmed: 32579877